Events & Presentations Events & Presentations Latest Corporate Presentation May 10, 2021 Checkmate Pharmaceuticals Corporate Overview – May 2021 Past Events Jefferies 2021 Virtual Healthcare Conference Jun 1, 2021 at 2:00 PM EDT Bank of America Securities 2021 Virtual Healthcare Conference May 12, 2021 at 1:15 PM EDT Jefferies London 2020 Virtual Healthcare Conference Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB Presentations World Congress of Melanoma/EADO Congress 2021. Krieg, Art. View presentation recording: CMP-001, a CpG-A TLR9 agonist package in a virus-l… World Congress of Melanoma/EADO Congress 2021. Diwakar, Davar. View presentation: Neoadjuvant combinations with innate immunity stimulation World Congress of Melanoma/EADO Congress 2021. Ribas, Antoni, et al. Source Abstract P-119. View poster: CMP-001-010: An Open-Label, Phase 2 Study to Evaluate Intratumoura… World Congress of Melanoma/EADO Congress 2021. Davar, Diwakar, et al. Source Abstract P-074. View poster: CMP-001-011: First-Line Vidutolimod (CMP-001) Plus Nivolumab Versu… AACR 2021. Luke, Jason, et al. Source Abstract 5231. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon… SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d… SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (… Pagination Current page 1 Page 2 Next page next › Last page last »
Events & Presentations Latest Corporate Presentation May 10, 2021 Checkmate Pharmaceuticals Corporate Overview – May 2021 Past Events Jefferies 2021 Virtual Healthcare Conference Jun 1, 2021 at 2:00 PM EDT Bank of America Securities 2021 Virtual Healthcare Conference May 12, 2021 at 1:15 PM EDT Jefferies London 2020 Virtual Healthcare Conference Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB Presentations World Congress of Melanoma/EADO Congress 2021. Krieg, Art. View presentation recording: CMP-001, a CpG-A TLR9 agonist package in a virus-l… World Congress of Melanoma/EADO Congress 2021. Diwakar, Davar. View presentation: Neoadjuvant combinations with innate immunity stimulation World Congress of Melanoma/EADO Congress 2021. Ribas, Antoni, et al. Source Abstract P-119. View poster: CMP-001-010: An Open-Label, Phase 2 Study to Evaluate Intratumoura… World Congress of Melanoma/EADO Congress 2021. Davar, Diwakar, et al. Source Abstract P-074. View poster: CMP-001-011: First-Line Vidutolimod (CMP-001) Plus Nivolumab Versu… AACR 2021. Luke, Jason, et al. Source Abstract 5231. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon… SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d… SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a… SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra… SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (… Pagination Current page 1 Page 2 Next page next › Last page last »
Jefferies London 2020 Virtual Healthcare Conference Nov 17, 2020 Supporting Materials Checkmate Pharmaceuticals Corporate Overview- November 2020 880.5 KB
World Congress of Melanoma/EADO Congress 2021. Krieg, Art. View presentation recording: CMP-001, a CpG-A TLR9 agonist package in a virus-l…
World Congress of Melanoma/EADO Congress 2021. Diwakar, Davar. View presentation: Neoadjuvant combinations with innate immunity stimulation
World Congress of Melanoma/EADO Congress 2021. Ribas, Antoni, et al. Source Abstract P-119. View poster: CMP-001-010: An Open-Label, Phase 2 Study to Evaluate Intratumoura…
World Congress of Melanoma/EADO Congress 2021. Davar, Diwakar, et al. Source Abstract P-074. View poster: CMP-001-011: First-Line Vidutolimod (CMP-001) Plus Nivolumab Versu…
AACR 2021. Luke, Jason, et al. Source Abstract 5231. Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon…
Vidutolimod (CMP-001) demonstrates improved response in noninflamed anti–PD-1 r… View slides: Vidutolimod (CMP-001) demonstrates improved response in noninflame… View presentation recording: Vidutolimod (CMP-001) demonstrates improved respon…
SITC 2020. Davar, Diwakar, et al. Source Abstract 612. View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (…
View poster: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (… View slides: Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (…
SITC 2020. Morris, Aaron, et al. Source Abstract 604. View poster: Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist d…
SITC 2020. Milhem, Mohammed, et al. Source Abstract 579. Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
Video: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist… View poster: Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) a…
SITC 2019. Kirkwood, John, et al. Source Abstract 11548/085. Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
Durable responses in anti-PD-1 refractory melanoma following intra-tumoral inje… View slides: Durable responses in anti-PD-1 refractory melanoma following intra…
SITC 2019. Davar, Diwakar, et al. Source Abstract 11648/034. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (…
Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 i… View slides: Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (…
